Skip to content
KVUE

Kenvue Inc.

Kenvue Inc. Q4 FY2023 earnings call

February 8, 2024 · fiscal period ended 2023-12

EPS · actual vs est

$0.31 / $0.28Beat +9.5%

Revenue · actual vs est

$3.67B / $3.78BMiss -3.1%
Ask about this call

Summary

Generated 2024-02-08

Management highlights

  • 2023 was transformational, with 5% organic growth across segments, regions, and categories, and initiation of dividend program.
  • 2024 priorities:
    • Reach more consumers with focus on 15 priority brands, strengthening brand experiences, driving innovation, and improving in-store execution.
    • Free up resources by accelerating gross margin expansion, exiting transition services agreements, and implementing modern systems for better demand forecasting.
    • Foster a culture with new performance management plan, clear goals, and accountability for Kenvuers.
View in transcript ↓

Segment performance

Self Care: 2023 organic growth of 8.4%, largest segment, with Adult Tylenol gaining share and innovation contributing. Essential Health: 3.6% organic growth, led by oral care and women's health, Listerine gum therapy successful. Skin Health and Beauty: 1.8% organic growth in 2023, disappointing Q4 due to US in-store execution issues; EMEA and Latin America strong, China weak; focus on improving in-store presence, consumer engagement, and innovation in US.

View in transcript ↓

Guidance

  • 2024 organic growth expected in range of 2% to 4%, Q1 organic growth flat.
  • Gross margin expected closer to 2021 levels.
  • Adjusted EPS range $1.10 to $1.20.
  • Marketing spend to increase ~15% to fuel brand growth.
View in transcript ↓

Risks

  • Uncertain macroeconomic conditions impacting consumer confidence.
  • Geopolitical issues affecting business operations.
  • Continued softness in China for Skin Health and Beauty.
  • In-store execution challenges in US Skin Health and Beauty.
View in transcript ↓

Q&A highlights

Q: On top line and organic forecast, A: Guidance reflects sequential improvement, but faces headwinds like China softness and Skin execution issues, yet confident in plans.

Q: On Q4 Skin Health and Beauty volume weakness, A: US underperformance due to execution issues, focus on enhancing in-store presence, consumer engagement, and innovation.

Q: On gross margin cadence, A: TSA savings phased, investment in marketing, gross margin to improve with value realization and efficiencies.

Q: On acetaminophen lawsuit, A: No update, going through dismissal process.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$0.31$0.28+9.5%
Revenue$3.67B$3.78B-3.1%

Transcript

February 8, 2024

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.